COUR CNP-106

The CNP-106 trial is currently recruiting people with myasthenia gravis (MG). CNP-106 is designed to help manage MG symptoms by potentially retraining the body’s immune system.

This investigational drug uses very tiny particles containing parts of the proteins that the immune system mistakenly attacks in MG, specifically from the acetylcholine receptor (AChR). This study aims to see if CNP-106 can improve MG symptoms.

Participants will receive either CNP-106 or a placebo. The treatment will be given through an IV on Day 1 and Day 8. Some participants will receive an additional treatment on Day 90.

Enrollment Contact:
Lupita Rodriguez
(602) 406-6641
Fulton.Research@DignityHealth.org